NCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
Clinical Trials
3 trialsNCT00805961 2021-12-08
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00515086 2011-09-22
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated